D.R. Horton’s Stock Jumps 8% On Surprise Earnings Beat
The stock of D.R. Horton (DHI) is up 8% after the largest U.S. homebuilder issued surprisingly strong quarterly financial results. The Arlington, Texas-based company reported earnings per share (EPS) of $3.36 U.S. for what was its fiscal third quarter. That beat the $2.88 U.S profit expected among analysts.Revenue in the period totaled $9.23 billion U.S., which was ahead of estimates that called for $8.76 billion U.S. Sales were down 7.4% from a year earlier. Management at D.R. Horton said buyer incentives helped to sustain home sales amid high interest rates and rising costs.Despite beating Wall Street forecasts, D.R. Horton is struggling with weak consumer spending, prompting it to offer incentives such as mortgage rate buydowns to boost demand.The company, which is the biggest homebuilder by volume in America, said affordability constraints and cautious consumer sentiment are likely to continue in the near term.“We expect our sales incentives to remain elevated and increase further during the fourth quarter, the extent to which will depend on the strength of demand…,” said D.R. Horton.Looking ahead, D.R. Horton lowered its revenue forecast for this year to $33.7 billion U.S. to $34.2 billion U.S., down from an earlier forecast of $33.3 billion U.S. to $34.8 billion U.S.The company expects to build between 85,000 and 85,500 new homes in 2025, compared with an earlier forecast of 85,000 to 87,000 houses.Prior to today (July 22), DHI stock declined 5% on the year to trade at $131.22 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


